計畫


第 1 到 20 筆結果，共 20 筆。

啟始時間標題P-Investigator經費來源
2021Precision Medicine of Radioiodine Refractory Papillary Thyroid CancerCHIA-CHI LINNational Science and Technology Council
2020Precision Medicine of Advanced Esophageal Squamous Cell CarcinomaCHIA-CHI LINNational Science and Technology Council
2020Taiwan Clinical Trial Consortium for Oncology Phase I TrialsCHIA-CHI LINNational Science and Technology Council
2019Phase I Trial Allocation Directed by Immunologically Classified Cancers Refractory to Anti-Pd-1 / Pd-L1 AntibodiesCHIA-CHI LINNational Science and Technology Council
2019Taiwan Clinical Trial Consortium for Oncology Phase I TrialsCHIA-CHI LINNational Science and Technology Council
2018Phase I Trial Allocation Directed by Immunologically Classified Cancers Refractory to Standard TherapyCHIA-CHI LINNational Science and Technology Council
2018Taiwan Clinical Trial Consortium for Oncology Phase I TrialsCHIA-CHI LINNational Science and Technology Council
2017Phase I Trial Allocation Directed by Immunologically Classified Cancers Refractory to Standard TherapyCHIA-CHI LINNational Science and Technology Council
2017Taiwan Clinical Trial Consortium for Oncology Phase I Trials VIICHIA-CHI LINNational Science and Technology Council
2016台灣癌症早期臨床試驗合作聯盟 VICHIA-CHI LINNational Science and Technology Council
2015Developing Novel Pharmacodynamic and Predictive Biomarkers of Molecularly Targeted Agents in Oncology Phase I TrialsCHIA-CHI LINNational Science and Technology Council
2015A Phase II Trial of BIBF1120 in Patients with Advanced FGFR3 Mutated, FGFR3 Overexpressed, or Fgfr3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-Based Chemotherapy (II)CHIA-CHI LINNational Science and Technology Council
2015Taiwan Clinical Trial Consortium for Oncology Phase I Trials (V)CHIA-CHI LINNational Science and Technology Council
2014Taiwan Clinical Trial Consortium for Oncology Phase I Trials (IV)CHIA-CHI LINNational Science and Technology Council
2014Developing Novel Pharmacodynamic and Predictive Biomarkers of Molecularly Targeted Agents in Oncology Phase I TrialsCHIA-CHI LINNational Science and Technology Council
2014A Phase II Trial of BIBF1120 in Patients with Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-Based Chemotherapy (I)CHIA-CHI LINNational Science and Technology Council
2013Developing Novel Pharmacodynamic and Predictive Biomarkers of Molecularly Targeted Agents in Oncology Phase I TrialsCHIA-CHI LINNational Science and Technology Council
2013Clinical Trials's Consortium, Resource Center of Translational Medicine: Oncology (III)CHIA-CHI LINNational Science and Technology Council
2012Clinical Trials Consortium, Resource Center of Translational Medicine---Oncology (II)CHIA-CHI LINNational Science and Technology Council
2011(100TR008) Clinical Trials' Consortium, Resource Center of Translational Medicine: Oncology Phase I Trials (I)CHIA-CHI LINNational Science and Technology Council